Gyros Protein Technologies Introduces Gyrolab Generic Anti-AAV Kit to Support Gene Therapy Development
17 Junio 2024 - 8:59AM
Business Wire
Ready-to-use kit enables detection of binding
antibodies against AAV vectors without the need for
serotype-specific assays
Gyros Protein Technologies AB, a pioneer in automated
nanoliter-scale immunoassays and leading provider of peptide
synthesizers today announced the introduction of its Gyrolab®
Generic Anti-Adeno Associated Virus (AAV) Kit. The new ready-to-use
kit facilitates the qualitative assessment of pre-existing binding
antibodies against AAV vectors, enabling screening in pre-clinical
and clinical settings. The kit supports identification of
pre-existing immunity that may interfere with the efficacy of
AAV-based gene therapy delivery.
The ready-to-use kit, designed to detect total binding
anti-capsid antibodies against the most commonly used AAV
serotypes, is the first of its kind on the market for assessing
pre-existing anti-AAV antibodies, streamlining the screening
process by eliminating the need for serotype-specific assay
development. Compared to other methods currently used for detecting
pre-existing binding antibodies, the kit removes the need for
capsid labelling, reducing variability and ensuring reproducible
data whilst requiring small quantities of viral capsids, preserving
precious drug volumes.
The kit is optimized for use on all Gyrolab systems and expands
the utility of the Gyrolab platform into the bioanalytical field of
AAV-based gene therapies. Automation with Gyrolab systems reduces
variability due to manual pipetting and speeds up workflows by
reducing assay development time and generating results within 90
minutes, helping to accelerate the development of novel gene
therapies.
Mark Vossenaar, General Manager, Biopharmaceutical
Development Division, Gyros Protein Technologies, commented:
“The new Gyrolab Generic Anti-AAV Kit is tailored to meet customer
needs in the bioanalysis of AAV-based gene therapeutics, focusing
on efficiency, resource, and time-savings. This innovative addition
expands our portfolio of ready-to-use kits, providing a rapid,
cost-effective solution for the detection of total binding
antibodies without necessitating serotype-specific assay
development or extensive optimization. Gyrolab Generic Anti-AAV Kit
provides our customers with convenience whilst ensuring robust and
reliable data. This allows for more informed decisions regarding
individual stratification following preexisting anti-AAV antibody
screening.”
For more information on the Gyrolab Generic Anti-AAV Kit, please
visit:
https://www.gyrosproteintechnologies.com/immunoassays/products/gyrolab-generic-anti-aav-kit
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240617414845/en/
Dr Ben Rutter Zyme Communications: Tel: +44 (0) 7920 770 935
Email: ben.rutter@zymecommunications.com